Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

Phase 1

Terminated

• Conditions: COVID-19 Vaccines
• Interventions: Biological: MVA-SARS-2-ST

• Registration Number: NCT05226390
• Lead Sponsor: Hannover Medical School

Brief Summary

This will be a phase I, single-center trial, including a total of 30 participants in two cohorts.

Cohort 1 (n=6): Healthy male or female adults aged 18 - ≤ 60 previously primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen.

Cohort 2 (n=24): Healthy male or female adults aged 18 - ≤ 60 primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen and subsequently booster immunized with any EU marketed mRNA vaccine

Both cohorts will be assigned to inhaled vaccination with MVA-SARS-2-ST

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-01-31
• Study First Submitted QC: 2022-02-04
• Study First Posted: 2022-02-07
• Study Start: 2022-02-24
• Primary Completion: 2023-11-21
• Study Completion: 2023-11-21
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-19
• Last Update Posted: 2024-01-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

The subject must not be enrolled before all inclusion criteria (including test results) are confirmed. Subjects meeting all of the criteria listed below will be included in the study.

1. Signed written informed consent from subject prior to any study-related procedure and willingness to comply with treatment and follow-up procedures

2. Healthy men or women, aged ≥ 18 ≤ 60 at day of inclusion having received either

   1. primary immunization (cohort 1) with any regimen using any EU marketed SARS- CoV-2 vaccine or
   2. subsequently booster immunization (cohort 2) with any EU marketed mRNA vaccine

   at least 3 months prior to enrollment

3. Adults with SARS-CoV-2 specific IgG concentration between 10 RU/ml and 1200 RU/ml determined by Anti-SARS-CoV-2-QuantiVac-ELISA (IgG)

4. Males or non-pregnant, non-lactating females of child-bearing potential with negative pregnancy test at screening who agree to comply with the applicable contraceptive requirements of the protocol (Section 3.4) from at least 14 days prior to vaccination and during the entire duration of the study.

   or

   Females without child-bearing potential defined as follows:

   • at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
   • hysterectomy or uterine agenesis or
   • ≥ 50 years and in postmenopausal state > 1 year or
   • < 50 years and in postmenopausal state > 1 year with serum FSH > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening

5. Normal pulmonary function: FEV1 predicted ≥ 80% and FEV1/FVC > 70%

6. Body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening

7. Subject is capable of understanding the investigational nature, potential risks and benefits of the clinical trial

Exclusion Criteria

Subjects are excluded from the study if any of the following criteria are met at screening or on dosing day.

1. Previous MVA or rMVA vaccination
2. Known allergy to the components of the SARS-CoV-2 vaccine product as chicken proteins or history of life-threatening reactions to vaccine containing the same substances
3. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine
4. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance; safety laboratory screening evaluation can be repeated a maximum of two times
5. Any finding in the medical history and physical examination deviating from normal and assessed as clinically relevant by the investigator
6. Evidence in the subject's medical history or in the medical examination that might influence the absorption, distribution, metabolism or excretion of the investigational medicinal product
7. Current smoking/ vaping or smoking /vaping in the previous year.
8. Clinically relevant findings in ECG
9. Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes
10. Asthma, chronic obstructive pulmonary disease or other lung disease
11. Respiratory tract infection in the 4 weeks prior to study treatment
12. Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child
13. Known intolerance to medication used during bronchoscopy, i.e. midazolam and lidocaine.
14. Treatment with ß-adrenoceptor antagonists
15. Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males)
16. Drug abuse or positive drug screening
17. Any positive result for HIV1/2, HCV antibody or HBs antigen testing
18. Moderate or severe illness and/or fever >38 °C within 1 week prior to vaccination
19. History of blood donation within 60 days of enrollment or plans to donate within the treatment phase
20. Participation in a clinical trial or use of an investigational product within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study
21. Investigator or employee of the study site or Sponsor with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, natural or adopted child) of the investigator or employee with direct involvement in the proposed study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1 x 107 IU/dose MVA-SARS-2-ST	MVA-SARS-2-ST	All Participants will receive a single booster dose of 1 x 107 IU MVA-SARS-2-ST in 0.5 mL as inhalation (total inhaled volume 0.5 mL)

Primary Outcome Measures

Name	Time	Method
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	day 7	Occurrence of solicited local reactogenicity signs and symptoms
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	day 7	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
Occurrence of unsolicited adverse events (AE) associated with MVA-SARS-2-ST	from day 0 to day 28 after vaccination	Occurrence of unsolicited adverse events (AE)
Occurrence of serious adverse events (SAE) associated with MVA-SARS-2-ST	through study completion, an average of 5 month	Occurrence of serious adverse events (SAE)
Change from baseline of pulmonary function associated with MVA-SARS-2-ST	day 0 and twice daily on days 1, 2, 3, 4, 5, 6, 7	Change from baseline of pulmonary function measured by peak flow as peak expiratory flow (PEF) frequently
Change of safety laboratory measures associated with MVA-SARS-2-S	day 1, 3, 7, 14, 28, 56, 140	Change from baseline of safety laboratory measures

Secondary Outcome Measures

Name	Time	Method
To evaluate immunogenicity of the candidate MVA-SARS-2-ST	day 14	Change from baseline of levels of binding antibodies against SARS-CoV-2 spike S1 protein measured by ELISA in (bronchial alveolar lavage) BAL on day 14

Trial Locations

Locations (1)

Hannover Medical School ZKS - Early Clinical Trial Unit at CRC Hannover; 🇩🇪 Hannover, Germany